CCRM, a company developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and McMaster Innovation Park (MIP) in Canada, have signed a Letter of Intent (LOI) to partner in the development of a biomanufacturing campus at MIP focused on regenerative medicine-based technologies and cell and gene therapies. The LOI expands a months-long relationship between CCRM and MIP, and formalizes their intent to co-develop a business around the construction and ope...